GILEAD SCIENCES SL

🇪🇸Spain

Country: 🇪🇸Spain

Ownership: -

Established: 1994-01-01

Employees: -

Market Cap: $95.8B

Website: http://www.gilead.com/about/worldwide-operations/europe/spain

Clinical Trials

Efficacy, Pharmacokinetics, and Safety of Presatovir in Hospitalized Adults With Respiratory Syncytial Virus (RSV) Infection

Phase 2

Completed

Conditions: Respiratory Syncytial Virus Infection

Interventions: Drug: Presatovir placebo
Drug: Presatovir

First Posted Date: 2014-05-12

Last Posted Date: 2018-09-24

Lead Sponsor: Gilead Sciences

Target Recruit Count: 189

Registration Number: NCT02135614

Locations: 🇺🇸
William Beaumont, Royal Oak, Michigan, United States
🇺🇸
Marshfield Clinic Research Foundation, Marshfield, Wisconsin, United States
🇺🇸
University of Washington, Seattle, Washington, United States

and more 40 locations

Efficacy and Safety of Sofosbuvir+Ribavirin in Genotype 2 HCV-infected U.S. Veterans With Cirrhosis

Phase 4

Completed

Conditions: Hepatitis C Virus Infection

Interventions: Drug: Sofosbuvir
Drug: RBV

First Posted Date: 2014-05-01

Last Posted Date: 2016-08-03

Lead Sponsor: Gilead Sciences

Target Recruit Count: 66

Registration Number: NCT02128542

Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF

Phase 3

Completed

Conditions: HIV-1 Infection

Interventions: Drug: F/TAF
Drug: FTC/TDF
Drug: Allowed third antiretroviral agent
Drug: FTC/TDF Placebo
Drug: F/TAF Placebo

First Posted Date: 2014-04-24

Last Posted Date: 2020-03-12

Lead Sponsor: Gilead Sciences

Target Recruit Count: 668

Registration Number: NCT02121795

Locations: 🇺🇸
National Jewish Health, Denver, Colorado, United States
🇺🇸
Dupont Circle Physician's Group, Washington, District of Columbia, United States
🇺🇸
Whitman-Walker Health, Washington, District of Columbia, United States

and more 74 locations

Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination and Sofosbuvir + Ribavirin for Subjects With Chronic Hepatitis C Virus (HCV) and Inherited Bleeding Disorders

Phase 2

Completed

Conditions: Chronic HCV Infection

Interventions: Drug: SOF
Drug: LDV/SOF
Drug: RBV

First Posted Date: 2014-04-22

Last Posted Date: 2016-12-06

Lead Sponsor: Gilead Sciences

Target Recruit Count: 122

Registration Number: NCT02120300

Evaluating Ventricular Arrhythmia in Subjects With Implantable Cardioverter Defibrillator or Cardiac Resynchronization Therapy-Defibrillator

Phase 2

Completed

Conditions: Ventricular Arrhythmia

Interventions: Drug: Eleclazine
Drug: Placebo to match eleclazine

First Posted Date: 2014-04-04

Last Posted Date: 2019-04-09

Lead Sponsor: Gilead Sciences

Target Recruit Count: 313

Registration Number: NCT02104583

Locations: 🇺🇸
Cardiovascular Associates of Mesa, Mesa, Arizona, United States
🇺🇸
Ohiohealth Corporation, Columbus, Ohio, United States
🇺🇸
Charlotte Heart and Vascular Institute, Port Charlotte, Florida, United States

and more 81 locations

Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination in Treatment-Naive and Treatment-Experienced Subjects With Chronic Genotype 4 or 5 HCV Infection

Phase 2

Completed

Conditions: Chronic Genotype 5 HCV
Chronic Genotype 4 HCV

Interventions: Drug: LDV/SOF

First Posted Date: 2014-03-07

Last Posted Date: 2018-11-19

Lead Sponsor: Gilead Sciences

Target Recruit Count: 85

Registration Number: NCT02081079

Safety, Tolerability, and Pharmacokinetics of Andecaliximab in Adults With Chronic Obstructive Pulmonary Disease (COPD)

Phase 1

Completed

Conditions: Chronic Obstructive Pulmonary Disease

Interventions: Drug: Placebo to match Andecaliximab
Drug: Andecaliximab

First Posted Date: 2014-03-04

Last Posted Date: 2020-09-09

Lead Sponsor: Gilead Sciences

Target Recruit Count: 11

Registration Number: NCT02077465

Locations: 🇺🇸
Advanced Pharma CR, LLC, Miami, Florida, United States
🇺🇸
University at Buffalo CTRC, Buffalo, New York, United States
🇺🇸
Compass Research, LLC, Orlando, Florida, United States

and more 2 locations

Safety and Efficacy of Sofosbuvir Plus Ribavirin in Treatment-Naive Adults With Chronic Genotype 1 or 3 HCV Infection

Phase 3

Completed

Conditions: Chronic HCV Infection

Interventions: Drug: Sofosbuvir
Drug: RBV

First Posted Date: 2014-02-28

Last Posted Date: 2016-10-25

Lead Sponsor: Gilead Sciences

Target Recruit Count: 117

Registration Number: NCT02074514

Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 or 4 HCV and HIV-1 Co-infection

Phase 3

Completed

Conditions: Hepatitis C Virus
HIV

Interventions: Drug: LDV/SOF
Drug: RBV

First Posted Date: 2014-02-27

Last Posted Date: 2018-11-16

Lead Sponsor: Gilead Sciences

Target Recruit Count: 335

Registration Number: NCT02073656

Efficacy and Safety of E/C/F/TAF (Genvoya®) in HIV-1/Hepatitis B Co-infected Adults

Phase 3

Completed

Conditions: HIV
HBV

Interventions: Drug: E/C/F/TAF

First Posted Date: 2014-02-25

Last Posted Date: 2018-11-16

Lead Sponsor: Gilead Sciences

Target Recruit Count: 79

Registration Number: NCT02071082

Locations: 🇺🇸
Be Well Medical Center PC, Berkley, Michigan, United States
🇺🇸
AHF Research Center, Beverly Hills, California, United States
🇺🇸
Barry M. Rodwick MD, Clearwater, Florida, United States

and more 21 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy